First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).

Abstract

Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age ≥ 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1-73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9-23.9) months. The median overall survival was not reached (95% confidence interval 24.6-not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis.

• Authors: Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Hokkaido Lung Cancer Clinical Study Group Trial
• Journal: Scientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 23140 (11 30 2021) ISSN: 2045-2322 [Electronic] England
• PMID: 34848786 (Publication Type: Journal Article, Multicenter Study, Observational Study)
• Copyright: © 2021. The Author(s).

Chemical References

• Acrylamides
• Aniline Compounds
• Antineoplastic Agents
• Protein Kinase Inhibitors
• osimertinib
• EGFR protein, human
• ErbB Receptors

Topics

• Acrylamides (pharmacology)
• Aged
• Aged, 80 and over
• Aniline Compounds (pharmacology)
• Antineoplastic Agents (pharmacology)
• Carcinoma, Non-Small-Cell Lung (genetics)
• ErbB Receptors (genetics)
• Exons
• Female
• Follow-Up Studies
• Humans
• Kaplan-Meier Estimate
• Lung Neoplasms (genetics)
• Male
• Mutation
• Oncogenes
• Prognosis
• Progression-Free Survival
• Protein Kinase Inhibitors (therapeutic use)
• Retrospective Studies
• Treatment Outcome